共 50 条
- [31] CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphomaBLOOD, 2019, 134 (07) : 626 - 635Sauter, Craig S.Senechal, BrigitteRiviere, IsabelleNi, AiBernal, YvetteWang, XiuyanPurdon, TerenceHall, MallourySingh, Ashvin N.Szenes, Victoria Z.Yoo, SarahDogan, AhmetWang, YongzengMoskowitz, Craig H.Giralt, SergioMatasar, Matthew J.Perales, Miguel-AngelCurran, Kevin J.Park, JaeSadelain, MichelBrentjens, Renier J.
- [32] Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphomaBONE MARROW TRANSPLANTATION, 2022, 57 (05) : 837 - 839Galli, EugenioSora, FedericaHohaus, StefanBellesi, SilviaAutore, FrancescoMetafuni, ElisabettaInnocenti, IdannaMarra, JohnFresa, AlbertoLimongiello, Maria AssuntaGiammarco, SabrinaLeccisotti, LuciaGuarneri, AndreaChiusolo, PatriziaLaurenti, LucaTeofili, LucianaPiccirillo, NicolaBacigalupo, AndreaSica, Simona
- [33] Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapyCELL STEM CELL, 2021, 28 (12) : 2062 - +Woan, Karrune, VKim, HansolBjordahl, RyanDavis, Zachary B.Gaidarova, SvetlanaGoulding, JohnHancock, BrianMahmood, SajidAbujarour, RamzeyWang, HongboTuininga, KatieZhang, BinWu, Cheng-YingKodal, BehiyeKhaw, MelissaBendzick, LauraRogers, PaulGe, Moyar QingBonello, GregMeza, MiguelFelices, MartinHuffman, JanelDailey, ThomasLee, Tom T.Walcheck, BruceMalmberg, Karl J.Blazar, Bruce R.Bryceson, Yenan T.Valamehr, BahramMiller, Jeffrey S.Cichocki, Frank
- [34] CD19 CAR-T Cell Therapy in Children with Relapsed and Refractory B-ALLBLOOD, 2021, 138Molostova, OlgaShelikhova, LarisaMuzalevsky, YakovKazachenok, AlexeyKhismatullina, RimmaAbugova, JuliaKurnikova, ElenaTrakhtman, PavelPershin, DmitryZubachenko, ViktoriaFadeeva, MariaPopov, Alexander M.Illarionova, OlgaMiakova, NataliaLitvinov, DmitryNovichkova, GalinaMaschan, AlexeyMaschan, Michael
- [35] Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic LeukemiaBLOOD, 2024, 144 : 2819 - 2819Yang, TingtingDong, YetianZhang, MingmingFeng, JingjingFu, ShanXiao, PingnanHong, RuiminXu, HuijunCui, JiazhenHuang, SimaoWei, GuoqingChang, Alex H.Huang, HeHu, Yongxian
- [36] CD19/CD22 Dual-Targeted CAR-TTherapy Active in Relapsed/Refractory DLBCLONCOLOGIST, 2020, 25 : S12 - S13不详
- [37] Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma (vol 136, pg 1632, 2020)BLOOD, 2023, 141 (15) : 1896 - 1896Tong, C.Zhang, Y.Liu, Y.Wang, YaoWu, ZhiqiangHan, Weidong
- [38] In Vitro Characterization of CD19 CAR T Cells Derived by Electroporation of mRNAMOLECULAR THERAPY, 2022, 30 (04) : 157 - 157Karalewitz, AndrewBrady, JamesHarris, MeganCameron, Mark J.
- [39] A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell MalignanciesBLOOD, 2020, 136Park, Jae H.Jain, NitinChen, AndyMcGuirk, Joseph P.Diaz, MonicaValamehr, BahramChu, Yu-WayeCastro, Januario E.
- [40] CD19 CAR T-CELLS FOR RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: REAL-WORLD DATA FROM LMU MUNICHJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A48 - A49Bucklein, V.Blumenberg, V.Schmidt, C.Rejeski, K.Ruzicka, M.Mueller, N.Reischer, A.von Baumgarten, L.Voelkl, A.Wagner, B.Humpe, A.Tischer, J.Stemmler, H.von Bergwelt, M.Subklewe, M.